

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
August 25, 2011

**USANA HEALTH SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

Utah

(State or other jurisdiction of incorporation)

0-21116  
(Commission File No.)

87-0500306  
(IRS Employer Identification  
Number)

3838 West Parkway Boulevard  
Salt Lake City, Utah 84120

(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On August 25, 2011, USANA Health Sciences, Inc. issued a press release announcing that it plans to expand its operations into France and Belgium, which will be the Company's 17<sup>th</sup> and 18<sup>th</sup> markets worldwide. The Company announced that it expects to begin operations in France and Belgium during the first quarter of 2012. A copy of the press release is furnished herewith as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference. The Company will also post the press release, along with this Form 8-K, on its corporate website, [www.usanahealthsciences.com](http://www.usanahealthsciences.com).

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit 99 Press release issued by USANA Health Sciences, Inc. dated August 25, 2011(furnished herewith).

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**USANA HEALTH SCIENCES, INC.**

**By:** /s/ G. Douglas Hekking

G. Douglas Hekking, Chief Financial Officer

Date: August 25, 2011

## **USANA Health Sciences Announces Plans to Expand Operations into France and Belgium**

SALT LAKE CITY--(BUSINESS WIRE)--August 25, 2011--USANA Health Sciences, Inc. (NYSE: USNA) today announced its plans to expand into France and Belgium in the first quarter of 2012. With the addition of these two markets, USANA will have operations in 18 markets worldwide.

According to the World Federation of Direct Selling Associations (WFDSA), France is the world's 10<sup>th</sup>--largest direct selling market, with estimated sales of more than \$2.4 billion annually. USANA's Western European office headquarters will reside in France.

Dave Wentz, USANA's Chief Executive Officer, said, "We are very excited about our decision to enter France and Belgium. We currently have a number of leaders and customers, particularly in our North America region, with existing ties to these markets. We expect this new expansion to support positive growth on both sides of the Atlantic."

---

## **About USANA**

USANA develops and manufactures high-quality nutritional, personal care, and weight-management products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, and the United Kingdom. Additionally, USANA's wholly-owned subsidiary, BabyCare, Ltd., operates a direct selling business in China. More information on USANA can be found at <http://www.usanahealthsciences.com>.

## **Safe Harbor**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with our international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

## **CONTACT:**

USANA Health Sciences, Inc.

Investors Contact:

Patrique Richards, 801-954-7961

Investor Relations

investor.relations (at) us.usana.com

or

Media Contact:

Dan Macuga, 801-954-7280

Vice President of Marketing & Public Relations

Dan.Macuga (at) us.usana.com